Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HAGOP M KANTARJIAN and WILLIAM K PLUNKETT JR.
HAGOP M KANTARJIAN
Connection Strength
2.750
WILLIAM K PLUNKETT JR
  1. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov; 13(11):1096-104.
    View in: PubMed
    Score: 0.432
  2. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010 Jan 10; 28(2):285-91.
    View in: PubMed
    Score: 0.353
  3. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8.
    View in: PubMed
    Score: 0.117
  4. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
    View in: PubMed
    Score: 0.104
  5. Sapacitabine for cancer. Expert Opin Investig Drugs. 2012 Apr; 21(4):541-55.
    View in: PubMed
    Score: 0.103
  6. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46.
    View in: PubMed
    Score: 0.091
  7. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
    View in: PubMed
    Score: 0.091
  8. Clofarabine in leukemia. Expert Rev Hematol. 2010 Feb; 3(1):15-22.
    View in: PubMed
    Score: 0.089
  9. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs. 2011 Apr; 29(2):323-31.
    View in: PubMed
    Score: 0.089
  10. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006 Mar 01; 106(5):1099-109.
    View in: PubMed
    Score: 0.068
  11. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 2005 May 15; 103(10):1985-95.
    View in: PubMed
    Score: 0.065
  12. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4079-88.
    View in: PubMed
    Score: 0.064
  13. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.
    View in: PubMed
    Score: 0.062
  14. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15; 9(17):6335-42.
    View in: PubMed
    Score: 0.058
  15. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9.
    View in: PubMed
    Score: 0.058
  16. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86.
    View in: PubMed
    Score: 0.056
  17. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73.
    View in: PubMed
    Score: 0.056
  18. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62.
    View in: PubMed
    Score: 0.054
  19. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58.
    View in: PubMed
    Score: 0.051
  20. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma. 1999 Aug; 34(5-6):511-8.
    View in: PubMed
    Score: 0.043
  21. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64.
    View in: PubMed
    Score: 0.031
  22. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
    View in: PubMed
    Score: 0.031
  23. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39.
    View in: PubMed
    Score: 0.029
  24. Clinical experience with fludarabine in leukaemia. Drugs. 1994; 47 Suppl 6:39-49.
    View in: PubMed
    Score: 0.029
  25. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7.
    View in: PubMed
    Score: 0.029
  26. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):568-74.
    View in: PubMed
    Score: 0.028
  27. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma. 1993 May; 10(1-2):43-8.
    View in: PubMed
    Score: 0.028
  28. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993 Mar 01; 81(5):1146-51.
    View in: PubMed
    Score: 0.028
  29. Chronic lymphocytic leukemia--correlation of response and survival. Leuk Lymphoma. 1993; 11 Suppl 2:167-75.
    View in: PubMed
    Score: 0.027
  30. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992 Mar; 10(3):406-13.
    View in: PubMed
    Score: 0.026
  31. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res. 1990 Nov 01; 50(21):6823-6.
    View in: PubMed
    Score: 0.024
  32. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5.
    View in: PubMed
    Score: 0.021
  33. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10; 26(2):196-203.
    View in: PubMed
    Score: 0.019
  34. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987 Jun 01; 47(11):3005-11.
    View in: PubMed
    Score: 0.019
  35. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986 Sep; 81(3):387-94.
    View in: PubMed
    Score: 0.018
  36. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60.
    View in: PubMed
    Score: 0.016
  37. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6.
    View in: PubMed
    Score: 0.016
  38. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1417-23.
    View in: PubMed
    Score: 0.015
  39. High-dose cytosine arabinoside in multiple myeloma. Eur J Cancer Clin Oncol. 1984 Feb; 20(2):227-31.
    View in: PubMed
    Score: 0.015
  40. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994; 14 Suppl 2:11-6.
    View in: PubMed
    Score: 0.015
  41. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83.
    View in: PubMed
    Score: 0.015
  42. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol. 1983 Nov; 1(11):689-94.
    View in: PubMed
    Score: 0.015
  43. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):13-20.
    View in: PubMed
    Score: 0.014
  44. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec; 36(1-2):57-65.
    View in: PubMed
    Score: 0.011
  45. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64.
    View in: PubMed
    Score: 0.010
  46. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998 Jul; 16(7):2321-31.
    View in: PubMed
    Score: 0.010
  47. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91.
    View in: PubMed
    Score: 0.009
  48. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9.
    View in: PubMed
    Score: 0.009
  49. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9.
    View in: PubMed
    Score: 0.008
  50. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994 Aug; 8(8):1269-74.
    View in: PubMed
    Score: 0.008
  51. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 01; 72(7):2155-60.
    View in: PubMed
    Score: 0.007
  52. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma. 1993 Jun; 10(3):187-93.
    View in: PubMed
    Score: 0.007
  53. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 01; 81(11):2878-84.
    View in: PubMed
    Score: 0.007
  54. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar; 9(4-5):343-50.
    View in: PubMed
    Score: 0.007
  55. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma. 1993; 10 Suppl:115-21.
    View in: PubMed
    Score: 0.007
  56. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia. 1992 Nov; 6 Suppl 4:140-1.
    View in: PubMed
    Score: 0.007
  57. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia. 1992; 6 Suppl 2:78-80.
    View in: PubMed
    Score: 0.006
  58. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia. Haematol Blood Transfus. 1990; 33:593-603.
    View in: PubMed
    Score: 0.006
  59. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989 Jul; 74(1):19-25.
    View in: PubMed
    Score: 0.005
  60. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15; 62(4):677-82.
    View in: PubMed
    Score: 0.005
  61. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol. 1986 Jul; 4(7):1079-88.
    View in: PubMed
    Score: 0.004
  62. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.